EUVIMEDEUVIMED entdecken
Crossref

Risk predictive model for the development of hepatocellular carcinoma before initiating long‐term antiviral therapy in patients with chronic hepatitis B virus infection

Junjie Chen, Tienan Feng, Qi Xu, Xiaoqi Yu, Yue Han, Demin Yu, Qiming Gong, Yuan Xue iD, Xinxin Zhang iD

Journal of Medical Virology · 2024

DOI: 10.1002/jmv.29884 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, 2024. Verfasst von Junjie Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Research Laboratory of Clinical Virology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shang…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Hepatitis B, Chronic, Liver Neoplasms, Antiviral Agents. Die Arbeit nennt 32 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shanghai Municipal Science and Technology Major Project, National Key Projects of Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

It is generally acknowledged that antiviral therapy can reduce the incidence of hepatitis B virus (HBV)‐related hepatocellular carcinoma (HCC), there remains a subset of patients with chronic HBV infection who develop HCC despite receiving antiviral treatment. This study aimed to develop a model capable of predicting the long‐term occurrence of HCC in patients with chronic HBV infection before initiating antiviral therapy. A total of 1450 patients with chronic HBV infection, who received initial antiviral therapy between April 2006 and March 2023 and completed long‐term follow‐ups, were nonselectively enrolled in this study. Least absolute shrinkage and selection operator (LASSO) and Cox regression analysis was used to construct the model. The results were validated in an external cohort ( n = 210) and compared with existing models. The median follow‐up time for all patients was 60 months, with a maximum follow‐up time of 144 months, during which, 32 cases of HCC occurred. The nomogram model for predicting HCC based on GGT, AFP, cirrhosis, gender, age, and hepatitis B e antibody (TARGET‐HCC) was constructed, demonstrating a good predictive performance. In the derivation cohort, the C‐index was 0.906 (95% CI = 0.869–0.944), and in the validation cohort, it was 0.780 (95% CI = 0.673–0.886). Compared with existing models, TARGET‐HCC showed promising predictive performance. Additionally, the time‐dependent feature importance curve indicated that gender consistently remained the most stable predictor for HCC throughout the initial decade of antiviral therapy. This simple predictive model based on noninvasive clinical features can assist clinicians in identifying high‐risk patients with chronic HBV infection for HCC before the initiation of antiviral therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularHepatitis B, ChronicLiver NeoplasmsAntiviral AgentsHumansMaleFemaleMiddle AgedAdultRisk FactorsNomogramsRisk AssessmentAgedHepatitis B virusIncidenceFollow-Up Studies

Stichwörter der Autor:innen

antiviral therapychronic hepatitis Bhepatocellular carcinomarisk predictive model

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Department of Infectious Diseases, Research Laboratory of Clinical Virology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Clinical Research Institute, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Institute of Hepatology, The Third People's Hospital of Changzhou, Changzhou, Jiangsu, China.
  • Department of Liver Diseases, The Third People's Hospital of Changzhou, Changzhou, Jiangsu, China.
  • Clinical Research Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

ORCID-Profile: Yuan Xue, Xinxin Zhang

Förderung

  • National Natural Science Foundation of China
  • Shanghai Municipal Science and Technology Major Project
  • National Key Projects of Infectious Diseases

Zitieren

APA

Chen, J., Feng, T., Xu, Q., Yu, X., Han, Y., Yu, D., Gong, Q., Xue, Y., & Zhang, X. (2024). Risk predictive model for the development of hepatocellular carcinoma before initiating long‐term antiviral therapy in patients with chronic hepatitis B virus infection. Journal of Medical Virology. https://doi.org/10.1002/jmv.29884

Vancouver

Chen J, Feng T, Xu Q, Yu X, Han Y, Yu D, et al. Risk predictive model for the development of hepatocellular carcinoma before initiating long‐term antiviral therapy in patients with chronic hepatitis B virus infection. Journal of Medical Virology. 2024. doi:10.1002/jmv.29884

BibTeX
@article{Chen2024,
  author = {Chen, Junjie and Feng, Tienan and Xu, Qi and Yu, Xiaoqi and Han, Yue and Yu, Demin and Gong, Qiming and Xue, Yuan and Zhang, Xinxin},
  title = {Risk predictive model for the development of hepatocellular carcinoma before initiating long‐term antiviral therapy in patients with chronic hepatitis B virus infection},
  journal = {Journal of Medical Virology},
  year = {2024},
  doi = {10.1002/jmv.29884}
}
Kostenlos starten →